Is Kovai Medical overvalued or undervalued?

As of 10 November 2025, Kovai Medical has moved from an attractive to a very attractive valuation grade. The company appears to be undervalued based on its current metrics. Key ratios include a PE ratio of 29.89, an EV to EBITDA of 16.66, and a ROE of 21.05%.
In comparison to its peers, Kovai Medical's PE ratio is significantly lower than that of Max Healthcare, which stands at 88.71, and Apollo Hospitals at 64.78, indicating a more favorable valuation. The company's recent stock performance has outpaced the Sensex over the last year, returning 11.59% compared to the Sensex's 5.09%, reinforcing the attractiveness of its current valuation.